期刊文献+

疏血通对髋部骨折患者凝血-纤溶功能影响的临床研究 被引量:4

A Clinical Study on the Changes of Coagulation-fibr inolysis System in the Patients Under going Fracture of Hip Receiving Treatment of Shuxuetong Complex
下载PDF
导出
摘要 目的:评估疏血通对髋关节手术患者术后凝血-纤溶系统的影响。方法:选择2002年7月~2003年4月髋部手术患者共57例,根据入院时间穴单双日雪分为治疗组穴34例雪和对照组穴23例雪,手术前3d开始分别采用疏血通和低分子肝素治疗,共10d,于用药前、术前、术后第1天、术后第3天、术后第7天,测定白陶土部分凝血活酶时间穴KPTT雪、凝血酶原时间穴PT雪、组织型纤溶酶原激活剂穴t-PA雪、组织型纤溶酶原激活剂抑制剂穴PAI雪、D-dimer、血小板聚集率,怀疑有深静脉血栓穴DVT雪者行静脉造影检查。结果:两组治疗前后KPTT,PT明显延长;治疗组t-PA活性明显增强穴P<0.05雪,D-dimer升高,PAI无明显变化,并抑制血小板聚集。结论:疏血通在预防和治疗髋关节术后静脉血栓形成中,不仅有抗凝作用,而且能激活纤溶系统,抑制血小板聚集,是一种安全有效的药物。 Objective:To investigate the change o f coagulation-fibrinolysis system in the postoperative patients undergoing fractu re of hip receiving treatment of Shuxuetong complex.Methods:In57consecutive patients undergoing fracture of hip between July2002and April2003were ra ndomly divided into treatment group(n=34)and control group(n=23).Trea tment group administrated Shuxuetong complex and control group adjusted dose sub cutaneous low molecular heparin calcium.In the day before administration,the d ay of preoperative and the1st,3rd,7th day of postoperative period,we deter mined KPTT,PT,t-PA,PAI,D-dimer and platelet aggregation level.Venography was be used to diagnose deep venous thromboses(DVT).Results:5of34(14. 7%)patients had venographically evident DVT in the treatment group and4of2 3(17.4%)in control group.In both groups,DVT decreased after administra tion,KPTT and PT were prolonged.But in treatment group,t-PA activity and D-dimer level increased,mean while the platelet aggregation was inhibited markedl y.There was no significant change of PAI activity.Conclusion:The prophylaxis and therapeutic effect and mechanism of Shuxuetong complex are related to inhibi tion of platelet aggregation,anticoagulation and activation of fibrinolysis in patients under going fracture of hip.
出处 《中国药业》 CAS 2004年第4期36-37,共2页 China Pharmaceuticals
关键词 水蛭素 蚓激酶 深静脉血栓 髋部骨折 Hirudin Lumbrukinase Deep Venous Thromboses Fracture of Hip
  • 相关文献

参考文献9

  • 1许俊堂,王荣山.血栓相关的血液学指标及其意义[J].中华检验医学杂志,2000,23(6):382-384. 被引量:37
  • 2杜文清,谭成云.凝血酶抑制剂水蛭素的抗凝作用[J].药学进展,1994,18(2):82-86. 被引量:9
  • 3王克林.证明重组水蛭素优于肝素的再研究[J].药学进展,1999,23(2):128-128.
  • 4Makajima N, Mihara H, Sumi H, et al. Characterization of potent fibrinolytic enzyme in earthworm[J]. Biosci Biotechnol Biochem, 1993:57:1728-1730.
  • 5Eduin L, Gary S, David R, et al. Substrate specificity of tissue- type plasminogen activator[J]. J Biol Chem, 1995,270(13):7558-7562.
  • 6Ridker PM, Hennekens CH,Stampfer M J, et al. Prospective study of endogenous tisse plasminogen activator and risk of stroke [J]. Lancet, 1994,343 .940 - 943.
  • 7张国平 张明 金惠铭.蚓激酶抗凝纤溶机制及其与t—PA的关系[J].微循环学杂志,1997,7(2):73-75.
  • 8赵明华.重组水蛭素和低分子肝素在总体髋复位后预防血栓栓塞并发症的比较[J].国外医药:内科分册,1998,25(9):406-406.
  • 9李春元.低分子肝素临床应用研究进展[J].国外医药(合成药.生化药.制剂分册),1998,19(6):340-344. 被引量:6

二级参考文献9

共引文献50

同被引文献69

引证文献4

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部